Keywords : highly active antiretroviral therapy
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 8, Pages 953-960
Background:The widespread use of highly active retroviral therapy (HAART) has indicated a dramatic reduction in impairment due to immunodeficiency. Several studies have shown that an adverse event of HAART on dyslipidemia and insulin resistance. This study aimed to assess changes in lipid profiles after HAART.
Methods:A prospective cohort study with a consecutive sampling method consists of 59 HIV-infected patientsreceiving HAART at Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia, from March-September 2020. Lipid profiles were measured at the initial time and after three months of HAART. The drug regimen was divided into two groups: Regimen
group 1 (tenofovir, lamivudine, efavirenz), and another regimen group (consist of 4 regimen group combination: zidovudine, lamivudine, efavirenz; tenofovir, emtricitabine, lopinavir/ritonavir; tenofovir, lamivudine, nevirapine, and tenofovir, lamivudine, rilpivirine). ANOVA paired t-test and chi-square test were used for statistical analysis(it is significant if p is<0.05).
Results:The mean age of the subjects was 32.1 ± 6.6 years old. About 76.3% of subjects were male. Regimen 1 was used by 88.1% of the subjects and another regimen only 11.9% of the subjects. There were 27 subjects (45.8%) were underweight. The proportion of subjects with lipid abnormalities after 3 months of HAART significantly higher in LDL-c and TG level (P= 0.002 and 0.021). Regimen group1 showed increased levels of total cholesterol (TC), LDL-c, and TG (P = 0.037, 0.041, and 0.001) after HAART.
Conclusion:Highly active retroviral therapy is associated with lipid profile changes in HIV patients after 3 months of therapy.